We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+41.99%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.04B
AUM Growth
+$1.98B
Cap. Flow
-$1.2B
Cap. Flow %
-17.09%
Top 10 Hldgs %
79.89%
Holding
87
New
12
Increased
14
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$51.7M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$19.5M
3
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$16.6M
4
QCOR
QUESTCOR PHARMA INC
QCOR
+$13.7M
5
XOMA
Xoma
XOMA
+$12.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$195M
2
VPHM
VIROPHARMA INC
VPHM
+$96M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$15.8M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$8.82M
5
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$8.22M

Sector Composition

Rank Sector Weight
1 Healthcare 48.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
51
United Therapeutics
UTHR
$22B
$4.41M 0.06%
+55,984
New +$4.09M
LITS
52
Lite Strategy Inc
LITS
$33.7M
$3.88M 0.06%
17,266
-8,515
-33% -$1.33M
ZGNX
53
DELISTED
Zogenix, Inc.
ZGNX
$3.7M 0.05%
250,125
– –
ASMB icon
54
Assembly Biosciences
ASMB
$700M
$3.51M 0.05%
20,264
– –
GERN icon
55
Geron
GERN
$977M
$3.35M 0.05%
1,058,000
– –
LGND icon
56
Ligand Pharmaceuticals
LGND
$5.71B
$3.18M 0.05%
117,660
– –
MDGL icon
57
Madrigal Pharmaceuticals
MDGL
$11.9B
$3.15M 0.04%
14,286
-25,687
-64% -$5.46M
TGTX icon
58
TG Therapeutics
TGTX
$8.31B
$3.02M 0.04%
+600,000
New +$3.67M
BLUE
59
DELISTED
bluebird bio
BLUE
$3.01M 0.04%
+8,609
New +$3.2M
WINT
60
DELISTED
Windtree Therapeutics Inc
WINT
$2.98M 0.04%
108,473
– –
ENTA icon
61
Enanta Pharmaceuticals
ENTA
$392M
$2.87M 0.04%
125,000
– –
RCPT
62
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$2.6M 0.04%
100,000
– –
SGMO
63
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.85M 0.03%
+176,707
New +$1.75M
RIGL icon
64
Rigel Pharmaceuticals
RIGL
$857M
$1.79M 0.03%
+50,000
New +$1.82M
OSUR icon
65
OraSure Technologies
OSUR
$268M
$1.46M 0.02%
243,467
– –
ACHN
66
DELISTED
Achillion Pharmaceuticals
ACHN
$1.37M 0.02%
455,000
– –
TSRO
67
DELISTED
TESARO, Inc.
TSRO
$1.21M 0.02%
31,218
– –
FOLD
68
DELISTED
Amicus Therapeutics
FOLD
$1.2M 0.02%
515,072
– –
CCXI
69
DELISTED
ChemoCentryx, Inc.
CCXI
$1.11M 0.02%
200,000
-175,000
-47% -$1.89M
TCRT icon
70
Alaunos Therapeutics
TCRT
$4.47M
$1M 0.01%
1,695
– –
EPZM
71
DELISTED
Epizyme, Inc
EPZM
$800K 0.01%
20,000
– –
CBST
72
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$318K ﹤0.01%
5,000
– –
SLXP
73
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$242K ﹤0.01%
3,621
-41,950
-92% -$2.89M
APEN
74
DELISTED
Apollo Endosurgery, Inc.
APEN
– –
-2,597
Closed -$880K
ALBO
75
DELISTED
Albireo Pharma Inc
ALBO
– –
-7,663
Closed -$961K
1 2
3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2013 Portfolio in Review

As of Q3 2013, Julian Baker held 87 positions worth $7.04B, up 39% from $5.06B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Julian Baker withdrew a net $1.2B in Q3 2013, closing 5 positions and reducing 15 holdings. Its most notable exit was Arqule Inc, an estimated $2.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 48% a quarter earlier.

Against the trend, Julian Baker opened a new position in Mirati Therapeutics, Inc. Common Stock worth $30M.

  • Julian Baker's largest Q3 2013 buy was Mirati Therapeutics, Inc. Common Stock: 1,980,074 shares worth $30M.
  • Julian Baker added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013, an estimated $51.7M increase.
  • Julian Baker's biggest Q3 2013 reduction was PHARMACYCLICS INC, cutting an estimated $195M.
  • Julian Baker fully exited Arqule Inc in Q3 2013, selling an estimated $2.04M.
  • Julian Baker's ten largest holdings make up 80% of its $7.04B portfolio in Q3 2013.
  • Julian Baker opened 12 new positions and closed 5 in Q3 2013.
  • Julian Baker's portfolio value rose 39% quarter-over-quarter to $7.04B.

Based on Baker Bros. Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.